In an interview with Pharmacy Times, Deanna Horner, PharmD, BCPS, discusses how pharmacists can serve as patient advocates in GLP-1 care and how direct access models may simplify the patient journey while preserving clinical oversight.

Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, discusses multimodal analgesia, acute pain pathways, opioid-tolerant patients, suzetrigine, and pharmacist-led interventions across health systems with Pharmacy Times.

A preclinical study demonstrates protective immunity against flu, COVID-19, and RSV without immune interference.

In this episode, 'BCMA Biology, Mechanisms of Action, and Unmet Needs in Relapsed/Refractory Multiple Myeloma,' the expert oncologists and oncology pharmacists explored the following questions: What is the biological rationale for targeting B-cell maturation antigen (BCMA) in multiple myeloma? What are the different types of BCMA-targeted therapies and what are the Food and Drug Administration (FDA)-approved options? How do the mechanisms of action differ for the 3 different types of BCMA-targeted therapies? What unmet needs in relapsed/refractory multiple myeloma (RRMM) are addressed by BCMA-directed therapies? What are the potential clinical benefits and risks of introducing B-cell maturation antigen (BCMA)-targeted therapies earlier in the treatment continuum?

Welcome back to another Pharmacy Times Practice Pearls series. In this episode titled, 'Rationale and Timing: The Evolving Role of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma,' Ryan Haumschild led the conversation about the following question: What are the potential clinical benefits and risks of introducing B-cell maturation antigen (BCMA)-targeted therapies earlier in the treatment continuum?

New findings show chronic kidney disease affects the same share of US adults as in 2013, though the disease is increasingly tied to diabetes and heart conditions.